Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market

BEIJING, Nov. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA),
a leading developer and provider of vaccines in China, announced today that it
will voluntarily transfer its stock exchange listing from the NYSE Amex to the
NASDAQ Global Market.
It is anticipated that Sinovac's common shares will commence trading on
NASDAQ on or about November 16, 2009. Sinovac will continue to trade under the
ticker symbol "SVA."
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "The
transfer of our stock listing to NASDAQ demonstrates our continued focus on
creating shareholder value. We appreciate the support that the NYSE Amex has
provided over the years. However, we believe a NASDAQ listing will provide
Sinovac with opportunities to increase investor and analyst interest and
provide our investors with a better environment for trading our shares. In
addition, as NASDAQ is globally recognized as a leading exchange for
biopharmaceutical companies, we believe a NASDAQ listing will also place us in
the same marketplace as our peers."
"NASDAQ is the home of innovative biotech and healthcare companies and we
are proud to welcome Sinovac, a pioneer in Chinese biotech and engineer of
China's homegrown H1N1 vaccine," said Mr. Bob McCooey, Senior Vice President
and Head of Global Listing of NASDAQ OMX Group.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's vaccine
products, including Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A
and B), Anflu(R) (influenza), Panflu(TM), Sinovac's pandemic influenza vaccine
(H5N1), and PANFLU.1(TM), Sinovac's H1N1 vaccine, have already been approved
for government stockpiling. Sinovac is developing vaccines for enterovirus 71,
universal pandemic influenza, Japanese encephalitis, and human rabies. Its
wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal rabies vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
For more information, please contact:

Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com

Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com

Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Helen G. Yang, Sinovac Biotech Ltd., +86-10-8289-0088 x9871, fax
+86-10-6296-6910, info@sinovac.com; Investors - Amy Glynn and Stephanie
Carrington, The Ruth Group, +1-646-536-7023 or +1-646-536-7017,
aglynn@theruthgroup.com or scarrington@theruthgroup.com; Media - Janine
McCargo, The Ruth Group, +1-646-536-7033, jmccargo@theruthgroup.com